← All trials
NCT05890521
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 2, 2022
- Primary completion
- Jun 16, 2022
- Completion date
- Jun 30, 2023
- First posted
- Jun 6, 2023
- Last posted
- Jun 6, 2023
- Enrollment
- 100000
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Lead sponsor
- Government of ChinaCollaborator
- Government of ChinaCollaborator
- Government of ChinaStudy chair
- Government of ChinaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.